Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups

Breast Cancer Research and Treatment

Volumn 130, Issue 2, 2011, Pages 599-608

  Van Den Broek, Alexandra J ^a   Broeks, Annegien ^a   Horlings, Hugo M ^a,c   Canisius, Sander V M ^a   Braaf, Linde M ^a   Langerød, Anita ^b   Van'T Veer, Laura J ^a   Schmidt, Marjanka K ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Breast cancer survival; Gene expression profiling; MDM2; Polymorphisms; TP53; Tumor subgroups

Indexed keywords

DNA; PROTEIN MDM2; PROTEIN P53; PROTEIN R72P; PROTEIN SNP309; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENE PRODUCT; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; MDM2 GENE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; R72P GENE; SNP309 GENE; TP53 GENE;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; GENES, NEOPLASM; GENETIC ASSOCIATION STUDIES; GERM-LINE MUTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION, MISSENSE; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MDM2; PTEN PHOSPHOHYDROLASE; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 82955203453     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1615-y     Document Type: Article

References (49)

1. Jin S, Levine AJ (2001) The p53 functional circuit. J Cell Sci 114:4139-4140 (Pubitemid 33138651)
2. Zhou BB, Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408:433-439
3. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331 (Pubitemid 27131374)
4. Bond GL, Hu W, Levine AJ (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5:3-8 (Pubitemid 40321795)
5. Michael D, Oren M (2003) The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13:49-58 (Pubitemid 36269180)
6. Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9:95-107
7. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26: 2157-2165 (Pubitemid 46536647)
8. Pharoah PD, Day NE, Caldas C (1999) Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 80:1968-1973 (Pubitemid 29391282)
9. Chompret A (2002) The Li-Fraumeni syndrome. Biochimie 84:75-82 (Pubitemid 34477095)
10. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV (1987) Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7:961-963 (Pubitemid 17004567)
11. Sakamuro D, Sabbatini P, White E, Prendergast GC (1997) The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15:887-898 (Pubitemid 27399550)
12. Walker KK, Levine AJ (1996) Identification of a novel p53 functional domain that is necessary for efficient growth sup-pression. Proc Natl Acad Sci USA 93:15335-15340 (Pubitemid 27009601)
13. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365 (Pubitemid 36278852)
14. Pim D, Banks L (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108:196-199 (Pubitemid 37541770)
15. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matla-shewski G (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19: 1092-1100 (Pubitemid 29046852)
16. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimaki A, von Smitten K, Aittomaki K, Heikkila P et al (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098-5103 (Pubitemid 41003693)
17. Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, van't Veer LJ, Pharoah PD, Easton DF, Shah M, Humphreys M, Dork T et al (2009) Combined effects of single nucleotide polymor-phisms TP53 R72P and MDM2 SNP309, and p53 expression on survival ofbreast cancer patients. Breast Cancer Res 11:R89
18. Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BA, Easton DF, Pharoah PP (2002) Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 62:3052-3057 (Pubitemid 34602394)
19. Vannini I, Zoli W, Tesei A, Rosetti M, Sansone P, Storci G, Passardi A, Massa I, Ricci M, Gusolfino D et al (2008) Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. Tumour Biol 29:145-151
20. Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y (2007) Associ-ation of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9:R34
21. Xu Y, Yao L, Zhao A, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Lu Y et al (2008) Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. Int J Cancer 122:2761-2766 (Pubitemid 351631378)
22. Martin AM, Kanetsky PA, Amirimani B, Colligon TA, Athana-siadis G, Shih HA, Gerrero MR, Calzone K, Rebbeck TR, Weber BL (2003) Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? J Med Genet 40:e34
23. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaiti-Pellie C et al (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age oftumour onset in Li-Fraumeni syndrome. J Med Genet 43:531-533 (Pubitemid 43927330)
24. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, Johnson N, Fletcher O, Peto J, Tommiska J et al (2007) Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 67:9584-9590 (Pubitemid 47535950)
25. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602 (Pubitemid 39535748)
26. Bond GL, Hu W, Levine A (2005) A single nucleotide poly-morphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65:5481-5484 (Pubitemid 40911143)
27. Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S (2006) Association of breast cancer out-come with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98:911-919 (Pubitemid 44018921)
28. Nechushtan H, Hamburger T, Mendelson S, Kadouri L, Sharon N, Pikarsky E, Peretz T (2009) Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations. BMC Cancer 9:60
29. Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R, Verhoef S, van't Veer LJ (2007) The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 15:110-114 (Pubitemid 44921674)
30. Faur N, Araud L, Laroche-Clary A, Kanno J, Toutain J, Yamori T, Robert J, Le Morvan V (2009) The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models. Br J Cancer 101:350-356
31. Takahashi S, Moriya T, Ishida T, Shibata H, Sasano H, Ohuchi N, Ishioka C (2008) Prediction of breast cancer prognosis by gene expression profile of TP53 status. Cancer Sci 99:324-332 (Pubitemid 351228487)
32. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmstrom P, Memeo L et al (2007) Poor prognosis in carcinoma is associated with a gene expression signature ofaberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 104:7564-7569 (Pubitemid 47185946)
33. 'T Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT et al (2002) Gene expression profiling predicts clinical outcome of breast cancer, Nature 415:530-536 (Pubitemid 34130608)
34. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009 (Pubitemid 35461656)
35. Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM, Armstrong N, van't Veer LJ, Ravdin PM (2009) Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol 10:1070-1076
36. Zhou W, Muggerud AA, Vu P, Due EU, Sorlie T, Borresen-Dale AL, Warnberg F, Langerod A (2009) Full sequencing of TP53 identifies identical mutations within in situ and invasive com-ponents in breast cancer suggesting clonal evolution. Mol Oncol 3:214-219
37. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168 (Pubitemid 28144151)
38. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endo-crine therapy in breast cancer. J Clin Oncol 17:1474-1481 (Pubitemid 29220854)
39. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I et al (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157-1167 (Pubitemid 43342504)
40. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET et al (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102:13550-13555 (Pubitemid 41420886)
41. Li L, Ross AH (2007) Why is PTEN an important tumor sup-pressor? J Cell Biochem 102:1368-1374 (Pubitemid 350223940)
42. Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6:184-192 (Pubitemid 43292562)
43. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J (1996) The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88:173-182 (Pubitemid 26065829)
44. Norberg T, Lennerstrand J, Inganas M, Bergh J (1998) Com-parison between p53 protein measurements using the lumino-metric immunoassay and immunohistochemistry with detection of p53 gene mutations using c DNA sequencing in human breast tumors. Int J Cancer 79:376-383 (Pubitemid 28359736)
45. Kyndi M, Alsner J, Hansen LL, Sorensen FB, Overgaard J (2006) LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer. Acta Oncol 45: 602-609 (Pubitemid 44167213)
46. Borresen-Dale AL (2003) TP53 and breast cancer. Hum Mutat 21:292-300
47. Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Borresen-Dale AL (2002) The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal car-cinomas. Cancer Epidemiol Biomarkers Prev 11:1684-1688 (Pubitemid 36020025)
48. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
49. Cheok CF, Verma CS, Baselga J, Lane DP (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8:25-37